1. Home
  2. CGEM

as 03-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Founded: 2016 Country:
United States
United States
Employees: N/A City: CAMBRIDGE
Market Cap: 506.1M IPO Year: 2021
Target Price: $32.86 AVG Volume (30 days): 411.9K
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -3.11 EPS Growth: N/A
52 Week Low/High: $7.90 - $30.19 Next Earning Date: 05-14-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): 278.37%

CGEM Daily Stock ML Predictions

Stock Insider Trading Activity of Cullinan Oncology Inc. (CGEM)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Jones Jeffrey Alan CGEM Chief Medical Officer Feb 25 '25 Sell $8.53 4,895 $41,754.35 174,164
SUMER JACQUELYN L CGEM Chief Legal Officer Feb 25 '25 Sell $8.53 3,756 $32,038.68 136,895
AHMED NADIM CGEM President and CEO Feb 25 '25 Sell $8.53 12,529 $106,872.37 430,621
Michaelson Jennifer CGEM Chief Scientific Officer Jan 6 '25 Sell $12.51 4,000 $50,040.00 95,760

Share on Social Networks: